婴儿同时接种4CMenB与MenACWY-CRM疫苗的免疫原性与安全性:3b期随机对照试验
在墨西哥和阿根廷开展的3b期开放多中心随机对照试验纳入750名健康婴儿,按1:1:1随机分组,在3、5、7和13月龄分别接种4CMenB与MenACWY-CRM联合接种、4CMenB单用或MenACWY-CRM单用。加强针后1个月,联合接种组对B群菌株的hSBA GMT比值(联合组/4CMenB组)为0.89–1.03,对ACWY群为1.05–2.48,所有GMT比值双侧95%CI下限均>0.5,达到非劣效主要目标;联合接种具免疫原性且耐受良好。
要点
- 婴儿联合接种4CMenB与MenACWY-CRM的免疫应答非劣于各自单独接种。
- 加强针后1个月所有GMT比值95%CI下限均>0.5,主要目标达成。
- 联合接种组与4CMenB组征集性不良事件较MenACWY组更常见。
核心结论
- 婴儿联合接种4CMenB与MenACWY-CRM所诱导的免疫应答非劣于疫苗单独接种,且联合接种具免疫原性、耐受良好。
研究设计与样本
- 3b期开放多中心随机对照试验(NCT02106390),在墨西哥和阿根廷纳入750名健康婴儿,按1:1:1随机分为4CMenB/MenACWY联合组、4CMenB组和MenACWY组,于3、5、7和13月龄接种。
- 主要目标为加强针后1个月评估联合接种相对单剂接种的免疫应答非劣效性,采用人血清杀菌试验(hSBA)评价免疫原性并评估安全性。
主要发现
- 加强针后1个月,B群菌株的hSBA GMT比值(4CMenB/MenACWY组比4CMenB组)为0.89–1.03,ACWY群为1.05–2.48,所有GMT比值双侧95%CI下限均>0.5。
- 所有组别及B群菌株中,基础免疫后1个月68–100%、加强针后1个月87–100%的儿童hSBA滴度≥5。
- ACWY群中所有组别基础免疫后≥96%、加强针后≥98%的儿童hSBA滴度≥4。
- 加强针后各菌株/血清群GMT较加强前升高≥5.99倍。
- 征集性不良事件在4CMenB/MenACWY组和4CMenB组较MenACWY组更常见,其他不良事件发生率组间相似;严重不良事件分别为联合组6例、4CMenB组13例、MenACWY组11例,其中1例(4CMenB组)被认为与疫苗相关。
临床怎么用
- 该试验支持在婴儿3、5、7和13月龄程序中同时接种4CMenB与MenACWY-CRM,免疫应答非劣于单独接种。
- 联合接种时需预期征集性不良事件较MenACWY单用更常见,应向家长做好告知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Invasive meningococcal disease has its highest incidence in infants. Co-administration of serogroup B (4CMenB) and quadrivalent conjugate (MenACWY-CRM) vaccines could protect against 5 clinically-relevant meningococcal serogroups. METHODS: This phase 3b, open, multicenter study (NCT02106390), conducted in Mexico and Argentina, enrolled and randomized (1:1:1) 750 healthy infants to receive either 4CMenB co-administered with MenACWY-CRM (4CMenB/MenACWY group), 4CMenB (4CMenB group), or MenACWY-CRM alone (MenACWY group) at ages 3, 5, 7 and 13 months. Non-inferiority of immune responses of co-administration to single administration of vaccines was assessed at 1 month post-booster dose (primary objective). Immunogenicity was evaluated pre- and 1 month post-primary and booster vaccinations using human serum bactericidal assay (hSBA). Safety was assessed. RESULTS: At 1 month post-booster vaccination, between-group hSBA geometric mean titer (GMT) ratios ranged from 0.89 to 1.03 for serogroup B strains (group 4CMenB/MenACWY over 4CMenB), and from 1.05 to 2.48 for ACWY serogroups (group 4CMenB/MenACWY over MenACWY). The lower limit of the 2-sided 95% confidence intervals for all GMT ratios was >0.5; the primary objective was demonstrated. Across all groups and serogroup B strains, 68-100% and 87-100% of children had hSBA titers ≥5 at 1 month post-primary and booster vaccination, respectively. For serogroups ACWY, ≥96% (post-primary vaccination) and ≥98% (post-booster vaccination) of children in all groups had hSBA titers ≥4. Post-booster vaccination, GMTs increased ≥5.99-fold from pre-booster values for each strain/serogroup. Solicited adverse events (AEs) were more frequent in groups 4CMenB/MenACWY and 4CMenB than in MenACWY; incidence of all other AEs was similar between groups. Serious AEs were reported for 6, 13, and 11 participants in groups 4CMenB/MenACWY, 4CMenB, and MenACWY, respectively; 1 (group 4CMenB) was considered vaccine-related. CONCLUSION: Immune responses elicited by co-administration of 4CMenB and MenACWY-CRM was non-inferior to single immunization. Co-administration of vaccines was immunogenic and well tolerated in infants. ClinicalTrials.gov: NCT02106390.
引用
- Macias Parra M, Gentile A, Vazquez Narvaez JA, et al. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial. Vaccine. 2018. PMID: 30414782. doi:10.1016/j.vaccine.2018.10.096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。